NASDAQ:RNA Avidity Biosciences (RNA) Stock Price, News & Analysis $6.48 +0.05 (+0.78%) As of 11/17/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Avidity Biosciences Stock (NASDAQ:RNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Avidity Biosciences alerts:Sign Up Key Stats Today's Range$6.45▼$6.9550-Day Range$6.43▼$10.5152-Week Range$6.36▼$16.77Volume352,108 shsAverage Volume229,349 shsMarket Capitalization$139.77 millionP/E RatioN/ADividend YieldN/APrice Target$33.00Consensus RatingModerate Buy Company Overview Avidity Biosciences is a biotechnology company focused on developing RNA-based medicines for diseases that affect muscle. Its Antibody Oligonucleotide Conjugate (AOC) platform combines antibodies with oligonucleotides to help deliver RNA-targeting treatments into muscle cells. The company’s research and clinical pipeline has included programs for neuromuscular disorders such as myotonic dystrophy type 1 and Duchenne muscular dystrophy. Avidity was founded in 2012 and is based in San Diego, California.AI Generated. May Contain Errors. Read More Avidity Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreRNA MarketRank™: 2.64721556088 of 5 starsAvidity Biosciences scored higher than 53% of companies evaluated by MarketBeat, and ranked 601st out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingAvidity Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 1 strong buy rating, 4 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialAvidity Biosciences has a consensus price target of $33.00, representing about 409.3% upside from its current price of $6.48.Amount of Analyst CoverageAvidity Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Avidity Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Avidity Biosciences are expected to decrease in the coming year, from ($3.56) to ($5.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avidity Biosciences is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avidity Biosciences is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvidity Biosciences has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.91% of the float of Avidity Biosciences has been sold short.Short Interest Ratio / Days to CoverAvidity Biosciences has a short interest ratio ("days to cover") of 16.07, which indicates bearish sentiment.Change versus previous monthShort interest in Avidity Biosciences has recently increased by 0.61%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvidity Biosciences does not currently pay a dividend.Dividend GrowthAvidity Biosciences does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.98 News SentimentAvidity Biosciences has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Avidity Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for RNA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Avidity Biosciences insiders have not sold or bought any company stock.Percentage Held by InstitutionsAvidity Biosciences has minimal institutional ownership at this time.Read more about Avidity Biosciences' insider trading history. Receive RNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RNA Stock News HeadlinesAvidity Biosciences, Inc. (NASDAQ:RNA) Stock Has Average Price Target of $40.80November 13, 2026 | americanbankingnews.comAtrium Therapeutics Reports Third Quarter 2026 Financial ResultsNovember 12, 2026 | prnewswire.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit. | Behind the Markets (Ad)Avidity Biosciences (RNA) Expected to Post Earnings on ThursdayNovember 11, 2026 | americanbankingnews.comAtrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026November 2, 2026 | prnewswire.comAtrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 SyndromeOctober 27, 2026 | prnewswire.comAtrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)October 20, 2026 | prnewswire.comYakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive FinancingOctober 20, 2026 | prnewswire.comSee More Headlines RNA Stock Analysis - Frequently Asked Questions How have RNA shares performed this year? Avidity Biosciences' stock was trading at $72.13 at the beginning of the year. Since then, RNA shares have decreased by 91.0% and is now trading at $6.48. How were Avidity Biosciences' earnings last quarter? Avidity Biosciences, Inc. (NASDAQ:RNA) released its earnings results on Thursday, November, 12th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.56. The biotechnology company earned $15.32 million during the quarter, compared to analyst estimates of $15 million. When did Avidity Biosciences IPO? Avidity Biosciences (RNA) raised $216 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 14,400,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO. How do I buy shares of Avidity Biosciences? Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Avidity Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avidity Biosciences investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Tesla (TSLA), Taiwan Semiconductor Manufacturing (TSM), Precision BioSciences (DTIL) and Editas Medicine (EDIT). Company Calendar Last Earnings11/12/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RNA CIK1599901 Webwww.aviditybiosciences.com Phone858-401-7900FaxN/AEmployees190Year Founded2013Price Target and Rating Average Price Target for Avidity Biosciences$33.00 High Price Target$72.00 Low Price Target$15.00 Potential Upside/Downside+409.3%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio10.46 Quick Ratio10.46 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.50 per share Price / Book0.68Miscellaneous Outstanding Shares21,570,000Free FloatN/AMarket Cap$139.77 million OptionableOptionable BetaN/A Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:RNA) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredAmerica's Biggest Bank… Down?About 4,800 Chase customers reported problems in just 15 minutes on Monday. Many couldn't log in or move money...Decentralized Masters | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.